Morningside Healthcare Savings Calculator

Entry

(You are 3 steps away from finding out your potential savings with Morningside Headline Brands)
Please enter your CCG and NHS email address below to gain access to the savings calculator

Information on this site is intended solely for healthcare professionals.
Personal information will not be stored at this point, it is required for HCP verification only. For more information please visit www.morningsidehealthcare.com/privacy

Prescribing Information: Sukkarto SR (metformin hydrochloride) 500mg, 750mg or 1000mg prolonged release tablets. Composition: Each 500mg tablet contains 390mg metformin base; 750mg contains 585mg metformin base; 1000mg contains 780mg metformin base. Refer to Summary of Product Characteristics (SmPC) before prescribing. Therapeutic Indications: Type 2 diabetes mellitus. Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose and/or increased HbA1C who are at risk and progressing towards type 2 diabetes mellitus despite lifestyle modifications for 3–6 months. Posology: Adults. Dosage and Administration: Monotherapy and combination with other oral antidiabetic agents: Starting dose of one 500mg SR tablet once daily with evening meals. Adjust dose on the basis of blood glucose measurements every 10 to 15 days in increments of 500mg, to a maximum dose of 2000mg, until glycaemic control achieved. A slow increase of dose may improve gastro-intestinal tolerability. If glycaemic control is not achieved consider Sukkarto SR 1000mg twice daily with food; then consider standard metformin tablets to a maximum of 3000mg daily. If transferring from another oral antidiabetic agent: discontinue and initiate Sukkarto SR at the dose indicated above. For patients already treated with metformin, the dose of Sukkarto SR should be equivalent to the daily dose of metformin in tablets (prolonged or immediate release). Combination with insulin: Usual starting dose of Sukkarto SR is one 500mg tablet once daily or the equivalent daily dose of metformin in tablets (prolonged or immediate release) up to a maximum of 1500mg or 2000mg for patients on 750mg or 1000mg tablets, respectively, with the evening meal; adjust insulin dose according to blood glucose measurements. Elderly: Adjust metformin dosage based on renal function; regular assessment of renal function is necessary. Children: Sukkarto SR should not be used in children. Contraindications: Hypersensitivity; acute metabolic acidosis (including lactic acidosis or diabetic ketoacidosis); diabetic pre-coma; severe renal failure (glomerular filtration rate [GFR] < 30mL/min); acute conditions with potential to alter renal function (including dehydration, severe infection or shock); acute or chronic disease which may cause tissue hypoxia (including acute and unstable heart failure, respiratory failure, recent myocardial infarction or shock); hepatic insufficiency; acute alcohol intoxication; alcoholism. Precautions and warnings: Lactic acidosis: metformin should be discontinued and contact with a healthcare professional recommended if dehydrated. Patients/care-givers should be informed of risk of lactic acidosis and if suspected metformin should be discontinued and immediate medical attention sought. Renal function: GFR should be assessed before initiation and at least annual thereafter, elderly patients and those with creatinine levels at the upper limit of normal should be checked two to four times a year. Special caution should be exercised in situations where renal function may become impaired. Regularly monitor cardiac and renal function in patients with stable chronic heart failure. Discontinue Sukkarto SR prior to using iodinated contrast agents, do not reinstitute until 48 hours afterwards and renal function is stable. Discontinue at the time of surgery with general, spinal or epidural anaesthesia and do not reinstate until 48 hours afterwards when renal function has been re-evaluated as stable. Patients should continue on their prescribed diet. Usual diabetes monitoring should be performed regularly. Caution advised when used in combination with insulin or other oral antidiabetics (e.g. sulphonylureas or meglitinides) due to possible hypoglycaemia. Interactions: Avoid alcohol and alcohol containing medications. Closely monitor renal function when using selective cyclooxygenase II inhibitors, ACE-inhibitors, angiotensin II receptor antagonists and diuretics. More frequent blood glucose monitoring required and dose adjustments may be necessary when using glucocorticoids (systemic and local) and sympathomimetics. Dose adjustment may be required during co-administration of organic cation transporters. Pregnancy & Lactation: During and prior to pregnancy, patients should not be treated with metformin but insulin is recommended to maintain glucose levels and lower the risk of foetal malformations. Metformin is excreted into breast milk. No adverse effects were observed in breast-fed newborns/infants; a decision should be made whether to discontinue nursing. Effects on ability to drive and use machines: Metformin alone does not affect the ability to drive or operate machinery. However, there is a risk of hypoglycaemia when used in combination with other anti-diabetic agents. Undesirable effects: Very common (≥1/10): nausea, vomiting, diarrhoea, abdominal pain, loss of appetite (most frequent during therapy initiation and majority resolve spontaneously). Common (≥1/100 to <1/10): taste disturbances. Very rare (<1/10,000): decrease of vitamin B12 absorption, lactic acidosis, isolated reports of liver function test abnormalities, hepatitis resolving upon discontinuation, skin reactions (erythema, pruritus, urticaria). Please refer to relevant SmPC for full information on adverse events. Overdose: Hypoglycaemia has not been seen with metformin doses of up to 85g although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks may lead to lactic acidosis which is a medical emergency and must be treated in hospital. Legal category: POM. Marketing Authorisation Numbers: Sukkarto SR 500mg: PL 20117/0110; 750mg: PL 20117/0277; 1000mg: PL 20117/0111. Price: 56 tablets Sukkarto SR 500mg: £2.38; 750mg: £2.87; 1000mg: £3.82. Marketing Authorisation Holder: Morningside Healthcare Ltd, 115 Narborough Road, Leicester LE3 0PA UK.

Date of Preparation: April 2019
SUK/PI/26874-0419

Please refer to full SmPC text before prescribing. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Morningside Healthcare Ltd.'s Medical Information Department on Tel: 0345 459 2137.

Prescribing Information: Ixyldone prolonged-release (PR) tablets. Blister pack of 28 tablets available as 5mg. Blister pack of 56 tablets available as 10mg, 15mg, 20mg, 30mg, 40mg, 60mg and 80mg tablet strengths. Composition: Each 5mg tablet contains 5mg oxycodone hydrochloride, corresponding to 4.5mg oxycodone; 10mg strength contains 10mg oxycodone hydrochloride, 9mg oxycodone; 15mg strength contains 15mg oxycodone hydrochloride, 13.5mg oxycodone; 20mg strength contains 20mg oxycodone hydrochloride, 17.9mg oxycodone; 30mg strength contains 30mg oxycodone hydrochloride, 26.9mg oxycodone; 40mg strength contains 40mg oxycodone hydrochloride, 35.9mg oxycodone; 60mg strength contains 60mg oxycodone hydrochloride, 53.8mg oxycodone; 80mg strength contains 80mg oxycodone hydrochloride, 71.7mg oxycodone. Always refer to the full Summary of Product Characteristics (SmPC) before prescribing. Indication: Severe pain, which can be adequately managed only with opioid analgesics in adults and adolescents aged ≥12 years. Dosage & Administration: initial dose 10mg twice daily for opioid naïve patients, although 5mg may be utilized to minimize AEs. At risk patients (low body weight, slow metabolism of medicinal products): half recommended dose if they are opioid naïve. Patients with renal or hepatic impairment: half recommended starting dose. Initial dose may be higher for patients switching from other opioids; 10–13mg oxycodone hydrochloride PR corresponds to approximately 20mg morphine sulphate PR; dosage should start conservatively at 50–75% of calculated dose. Not indicated for acute/breakthrough pain; 1/6 equianalgesic daily dose may be used as rescue medication however use of rescue administration more than twice daily indicates need for dose review. Dose adjustments should not be made more often than once every 1–2 days until a stable twice daily administration is reached. Following an increase from 10mg to 20mg twice daily, dose adjustments should be made in steps of 1/3 of the daily dose. Majority of patients benefit from even distribution (same dose in morning and evening) however it may be advantageous to distribute unevenly for some patients. In general, the lowest effective dose should be chosen. For non-malignant pain: 40mg is generally sufficient. For malignant pain: 80–120mg may be required; maximum daily dosage 400mg; >400mg can be considered on an individual basis. Regular monitoring required for long-term treatment. Discontinuation: taper dose gradually to prevent withdrawal. Contraindications: Hypersensitivity to the active substance or any of the excipients. Severe respiratory depression with hypoxia/hypercapnia. Severe COPD. Cor pulmonale. Severe bronchial asthma. Paralytic ileus. Acute abdomen, delayed gastric emptying Precautions and Warnings: Must be swallowed whole, must not be chewed, divided or crushed. Avoid concomitant alcohol. Patients who have venous injection abuse: tablet excipients may cause local tissue necrosis, lung granulomas or other potentially fatal events. Respiratory and cardiac depression: elderly/debilitated patients at highest risk; can lead to increased carbon dioxide concentration in the blood and cerebrospinal fluid; can cause severe decrease in blood pressure. Long-term use can cause tolerance or dependence (primary dependence potential); hyperalgesia may very rarely occur with high doses. Caution required in elderly or debilitated patients, severe lung, hepatic or renal impairment, myxoedema, hypothyroidism, Addison’s disease, intoxication psychosis, prostatic hypertrophy, adrenocortical insufficiency, alcoholism, known opioid dependence, delirium tremens, pancreatitis, biliary tract disease, biliary or ureteric colic, inflammatory bowel disorders, conditions with increased brain pressure, disturbances of circulatory regulation, epilepsy or seizure tendency and following MAO inhibitor use within the last two weeks. Closely monitor patients with severe hepatic impairment. Bowel surgery: usage not recommended pre-operatively or within 12–24hrs post-operatively. Warn athletes: usage may cause a positive reaction to anti-doping tests. Interactions: Other opioids, alcohol and CNS depressants (sedatives, hypnotics, phenothiazines, neuroleptics, anaesthetics, antidepressants, muscle relaxants) can enhance adverse effects of oxycodone, particularly respiratory depression. Interaction with MAO inhibitors may cause CNS excitation or depression with hyper- or hypotensive crisis. Increased plasma concentrations necessitating oxycodone dose adjustment may be observed with concomitant use of CYP2D6 inhibitors (such as paroxetine, quinidine) or CYP3A4 inhibitors (such as macrolide antibiotics, azolantifungals, protease inhibitors, cimetidine and grapefruit juice). Reduced plasma concentrations necessitating oxycodone dose adjustment may be observed with concomitant use of CYP3A4 inducers (such as rifampicin, carbamazepine, phenytoin, St John’s Wort). Concomitant use of coumarin anticoagulants may cause clinically relevant increase or decrease in INR. Pregnancy and Lactation: avoid use during pregnancy or lactation. If used during last 3–4 weeks of pregnancy monitor infants for respiratory depression. Withdrawal may be observed in newborns of mother’s undergoing oxycodone treatment. May be secreted in breast milk therefore may cause respiratory depression in newborn. Effects on ability to drive and use machinery: major influence at initiation and following dose adjustment; minor influence with stable therapy. Advise patients of likely impact on ability to drive and operate machinery, patients should not drive until they are aware how the medicine affects them. It is an offence to drive under the influence of this medicine, however driving is permitted if taken as prescribed and not affecting ability to drive safely. Adverse Events: Please refer to relevant SmPC for full information on adverse events. Very common: somnolence, dizziness, headache, constipation, nausea, vomiting, pruritus. Common: anorexia, decreased appetite, changes in mood/activity/cognitive performance, asthenia, tremor, dyspnoea, bronchospasm, dry mouth (rarely accompanied by thirst/difficulty swallowing), abdominal pain, diarrhoea, dyspepsia, rash, hyperhidrosis, micturition disturbance, asthenic conditions. Other less common side effects are listed in the relevant SmPC. Overdose: abuse of high doses can be fatal. Symptoms of overdose include: miosis, respiratory depression, somnolence, reduced skeletal muscle tone, drop in blood pressure. Please refer to relevant SmPC for full information regarding management of overdose. Legal Category: POM. Price: Basic NHS cost for 28 tablets: 5mg £3.12; Basic NHS cost for 56 tablets: 10mg £6.25; 15mg £9.52; 20mg £12.51; 30mg £19.05; 40mg £25.04; 60mg £38.11; 80mg £50.09. Marketing Authorisation Number: 5mg: PL 20117/0305; 10mg PL 20117/0306; 15mg PL 20117/0307; 20mg PL 20117/0308; 30mg PL 20117/0309; 40mg PL 20117/0310; 60mg PL 20117/0311; 80mg PL 20117/0312. Marketing Authorisation Holder: Morningside Healthcare Ltd, 115 Narborough Road Leicester, LE3 0PA, United Kingdom.

Date of Preparation: June 2019
Code: IXY/PI/26980-0619

Please refer to full SmPC text before prescribing. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Morningside Healthcare Ltd.'s Medical Information Department on Tel: 0345 459 2137.

Prescribing Information: Bimizza® 150 microgram (mcg)/20mcg uncoated tablets (Bimizza 150/20); Cimizt® 150mcg/30mcg uncoated tablets (Cimizt 150/30); Levest® 150mcg/30mcg coated tablets (Levest 150/30); Lizinna® 250mcg/35mcg uncoated tablets (Lizinna 250/35); Yacella® 0.03 milligrams (mg)/3mg uncoated tablets (Yacella 0.03/3). Composition: Bimizza 150mcg desogestrel and 20mcg ethinylestradiol; Cimizt 150mcg desogestrel and 30mcg ethinylestradiol; Levest 150mcg levonorgestrel and 30mcg ethinylestradiol; Lizinna 250mcg norgestimate and 35mcg ethinylestradiol; Yacella 0.03mg ethinylestradiol and 3mg dropirenone. Always refer to the full Summary of Product Characteristics (SmPC) before prescribing. Indication: Oral contraception. The decision to prescribe should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE compares with other combined hormonal contraceptives (CHCs). Bimizza and Cimizt: Not indicated during pregnancy. Yacella: Not indicated prior to menarche. Lizinna: Not indicated prior to menache or in post-menopausal women. Dosage & Administration: One tablet daily, at about the same time, for 21 consecutive days, starting on Day 1 of the normal menstrual cycle. Start each subsequent pack after a 7-day tablet-free interval, when a withdrawal bleed will occur usually on the 2nd or 3rd day (2nd to 4th for Lizinna) but may not have finished before the next pack is started. Please refer to the relevant SmPC for full advice on starting combined oral contraceptives (COCs), switching from a different contraceptive method, and management of missed tablets or gastrointestinal disturbances (including vomiting and diarrhoea). Contraindications: Please refer to the relevant SmPC for full details. Presence, history or patients at risk of (including hereditary or known predisposition for): venous thrombosis (VTE), arterial thrombosis (ATE, including myocardial infarction) or prodromal conditions (transient ischaemic attack and angina pectoris). High risk of VTE or ATE due to multiple risk factors, or the presence of serious risk factors including: diabetes mellitus with vascular symptoms, severe hypertension and severe dyslipoproteinaemia. History of migraine with focal neurology. Liver tumours or severe hepatic disease with currently abnormal liver function tests. Known or suspected sex-steroid influenced malignancies. Hypersensitivity to active substance or excipients of the tablet; rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption. Concomitant ombitasvir, partiaprevir, ritonavir or dasabuvir. Additional Product Specific Contraindications: Bimizza, Cimizt, Levest and Yacella: undiagnosed vaginal bleeding. Bimizza and Cimizt: pancreatitis, and history thereof if associated with severe hypertriglyceridaemia. Cimizt, Lizinna and Yacella: Major surgery with prolonged immobilization. Levest: Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency. Yacella: Severe renal insufficiency or acute renal failure. Precautions & Warnings: Please refer to the relevant SmPC for full information. Take a complete history, conduct a physical examination and rule out pregnancy prior to starting or resuming COC use. Weigh benefits of COC use against possible risks and discuss with the patient before use. Include full discussion of individual risk factors, how risks are highest during the first ever year of use or following a pill-free interval of at least a month, the symptoms of VTE and ATE, and advise what to do in the event of a suspected thrombosis or first appearance of risk factors. Instruct patients to read the user leaflet carefully and adhere to advice; draw attention to the information on VTE, and ensure the woman understands the VTE risk and the relative risk of COCs containing levonorgestrel, norgestimate or norethisterone. If multiple risk factors for ATE and/or VTE are present they may constitute a contraindication; total risk should be considered before prescribing. Increased risk of thromboembolism during puerperium must be considered. Discontinue if thrombosis is suspected or confirmed. Please consult SmPC for full information on risk factors for VTE and ATE. Discontinue if clinically relevant increases in blood pressure occur or in the case of preexisting hypertension with either constantly elevated blood pressure or inadequate response to antihypertensives. Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use. Depression can be serious and is a well-known risk factor for suicidal behaviour and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment. May induce/exacerbate symptoms of angioedema in women with hereditary angioedema. Acute or chronic disturbances of liver function may necessitate discontinuation until liver function returns to normal. Discontinue if cholestatic jaundice/cholestatis-related pruritus previously experienced during pregnancy or sex steroid use recurs. Monitor patients with diabetes during the first months of use. Worsening of endogenous depression, epilepsy, Crohn’s disease and ulcerative colitis have been reported during COC use. Chloasma may occasionally occur, especially in women with history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation during use. Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases. As with all COCs irregular bleeding may occur, especially during the first months of use; evaluate bleeding after approximately three cycles. If bleeding irregularities occur after three months, or previously regular cycles, further diagnostic procedures should be considered. Patients should be advised to contact their physician in the event of aggravation, exacerbation or first appearance of any of the aforementioned conditions so discontinuation can be considered. Please refer to the SmPC for information on other conditions reported with COC usage. Presence or family history of hypertriglyceridaemia may increase risk of pancreatitis when using COCs. Patients who develop an increase in frequency or severity of migraine should discontinue use and seek medical advice. A possible increased risk of cervical cancer has been reported with long-term COC use. Slightly increased risk of breast cancer has been reported in COC users, though no direct causation has been shown. This may be due to an earlier diagnosis, biological effects of the pill or a combination of both. In rare cases, hepatic tumours have been reported in users of oral contraceptives. Advise women not to smoke if they wish to use a CHC; smokers ≥35 years of age should be strongly advised to use a different method of contraception. Additional Product Specific Precautions & Warnings: Bimizza, Cimizt and Yacella: Risk of endometrial and ovarian cancer is reduced with 50mcg ethinylestradiol, whether this applies to lower-dosed COCs remains unconfirmed. Levest: Consider stopping prior to long-term immobilization due to surgery or trauma. Levest: Depressive food has been reported during pregnancy and COC use, however association with COCs is inconclusive. Lizinna: A small proportion of women will have persistent hypertriglyceridemia while on the Pill; changes in serum triglycerides and lipoprotein levels have been reported. Incidence of the following should be considered prior to prescribing: diabetes without vascular involvement, decreased glucose tolerance, asymptomatic gall bladder disease or cholecystectomy, benign liver tumours. Yacella: 72mg lactose per tablet; patients on a lactose-free diet should take this into consideration. Check serum potassium during first treatment cycle in patients with renal insufficiency and pre-treatment serum potassium in the upper treatment range, particularly during concomitant use of potassium sparing medicinal products. Interactions: Refer to the relevant SmPC for full details. Consult prescribing information of concomitant medications for potential interactions. Certain medications may increase COC clearance, affect efficacy and lead to contraceptive failure and/or breakthrough bleeding. Drugs that increase gastrointestinal motility may reduce hormone absorption. Drugs that induce hepatic microsomal enzymes may increase clearance of sex hormones, including barbiturates, phenytoin, primidone, carbamazepine, rifampicin, bosentan and HIV-medication, and possibly: oxycarbazepine, topiramate, felbamate, griseofulvin and medicines containing Hypericum perforatum (St. John’s Wort). Contraceptive failures have also been reported with antibiotics. Women on short-term treatment with medications known to have potential interactions with COCs (including antibiotics) should use a barrier method during concomitant use and for 7 days following discontinuation (28 days for rifampicin or liver enzyme-inducing drugs). An alternative reliable and non-hormonal method of contraception is recommended for women on long-term treatment with hepatic enzyme-inducing active substances. If concomitant medicinal product administration runs beyond the end of the tablets in the COC blister pack, the next pack should be started without the usual tablet-free interval. COCs may interfere with the metabolism of other compounds and therefore increase (cyclosporin) or decrease (lamotrigine) their plasma and tissue concentrations. COCs may influence the results of certain laboratory tests, including biochemical parameters of the liver, thyroid, adrenal and renal function, serum levels of proteins, parameters of carbohydrate metabolism, parameters of coagulation and fibrinolysis. Additional Product Specific Interactions: Levest: Certain antibiotics may decrease ethinylestradiol serum concentrations. HIV protease (e.g. ritonavir) may affect hepatic metabolism. Lizinna: Additional barrier method is recommended both during and for 56 days after discontinuation of concomitant modafinil. Interactions can with eslicarbazepine acetate, (fos)aprepitant, modafinil, non-nucleoside reverse transcriptase inhibitors, rifabutin, rufinamide. Drugs that increase gastrointestinal motility may reduce hormone absorption. Treatment with activated charcoal will compromise absorption of steroid hormones. Concomitant colesevelam has been shown to significantly decrease the AUC of ethinylestradiol; no interaction was seen when the contraceptive was given four hours before colesevelam. Drug interactions resulting in an increased clearance of sexual hormones may also impair contraceptive efficacy. Pregnancy & Lactation: Not indicated during pregnancy; treatment should be withdrawn immediately if pregnancy occurs. Not recommended during breastfeeding, particularly ≤6 weeks post-partum for Lizinna. Cimizt, Lizinna or Yacella: Increased risk of VTE during the postpartum period should be considered when re-starting. Effects on ability to drive & use machinery: Levest and Lizinna: No or negligible influence. Bimizza, Cimizt and Yacella: No studies on the effect on the ability to drive and use machinery have been performed, however, none observed for other COC users. Adverse Events: The most commonly reported adverse event in COC users in headache. COC use is also associated with an increased risk of arterial and venous thromboembolic events, hypertension, liver tumours and chloasma. In women with hereditary angioedema exogenous estrogen may induce of exacerbate symptoms of angioedema. Refer to relevant SmPC for full information on adverse events. Overdose: Levest and Lizinna: No serious effects have been reported with overdose. Bimizza, Cimizt and Yacella: no data available; nausea, vomiting and slight vaginal bleeding have been reported with COC overdose. Refer to relevant SmPC for full information on all adverse events. Additional Product Specific Adverse Reactions: Bimizza: Very common (>1/10): weight increase; irregular bleeding. Common/uncommon (<1/10 to >1/1,000): fluid retention, decreased libido, depressed or altered mood, headache, dizziness, nervousness, migraine, hypertension, nausea, vomiting, acne, rash, urticaria, amenorrhoea, breast tenderness, pain, or hypertrophy, metrorrhagia. Cimizt: Very common (>1/10): irregular bleeding, weight increase. Common/uncommon events (<1/10 to >1/1,000): fluid retention, decreased libido, depressed or altered mood, headache, dizziness, nervousness, migraine, hypertension, nausea, vomiting, acne, rash, urticaria, amenorrhoea, breast pain, breast tenderness, breast hypertrophy, metrorrhagia. Levest: Common (<1/10 to ≥1/100): nausea, abdominal pain, weight increase, depressed or altered mood, breast tenderness, breast pain, rash. Lizinna: Very common (≥1/10): headache, gastrointestinal disorder, vomiting, diarrhoea, nausea, dysmenorrhoea, metrorrhagia, abnormal withdrawal bleeding. Common/uncommon (<1/10 to ≥1/1000): urinary tract or vaginal infection, hypersensitivity, fluid retention, altered mood, depression, nervousness, insomnia, migraine, dizziness, gastrointestinal or abdominal pain, abdominal distension, constipation, flatulence, acne, rash, muscle spasms, pain in extremity, back pain, amenorrhoea, genital discharge, breast pain, chest pain, oedema, asthenic conditions, weight increase. Yacella: Common (<1/10 to ≥1/100): depressed mood, headache, migraine, nausea, menstrual disorders, intermenstrual bleeding, breast pain, breast tenderness, leukorrhoea, vaginal moniliasis. Legal Category: POM. Price: Bimizza 3 x 21 tablets £5.04; Cimizt 3 x 21 tablets £3.80; Levest 3 x 21 tablets £1.80; Lizinna 3 x 21 tablets £4.64; Yacella 3 x 21 tablets £8.30. Marketing Authorisation Number: Bimizza PL 20117/0091; Cimizt PL 20117/0231; Levest PL 20117/0044; Lizinna PL 20117/0220; Yacella PL 20117/0134. Marketing Authorisation Holder: Morningside Healthcare Ltd, 115 Narborough Road Leicester, LE3 0PA United Kingdom.

Date of Preparation: February 2019
Code: COM/PI/26709-0219

Please refer to full SmPC text before prescribing. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Morningside Healthcare Ltd.'s Medical Information Department on Tel: 0345 459 2137.